Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Tanta University | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Hepatocellular carcinoma is multifactorial in etiology and complex in pathogenesis, the blend of risk factors differs in different parts of the world, and this may explain in part the diverse biologic characteristics of HCC in different populations .
Exposure to aflatoxin is an additional risk factor for the development of HCC, through damage of DNA in liver cells and mutation in p53 tumor suppressor gene . A previous study showed that aflatoxin B1 has a considerable role in the development of HCC among Egyptians .
Clinical studies have shown that AFB1 selectively targets at the third base position of codon 249 of the human p53 gene, a known mutational hotspot in human hepatocellular carcinoma (HCC) . A significant association between aflatoxin exposure and HCC has been reported in hyperendemic areas . A synergistic interaction between AFB1 exposure and viral hepatitis B (HBV) infection on HCC risk has been reported in several epidemiologic studies.
Aflatoxin exposure may be associated with advanced liver disease in chronic hepatitis C (HCV) patients. Levels of AFB1-albumin/albumin were significantly related to ultrasono-graphic hepatic parenchyma scores in anti-HCV-positive subjects .
Hepatocellular carcinoma (HCC) is the fifth most common malignancy in the world and the third most common cause of cancer-related deaths complicating liver cirrhosis in most cases.
In Egypt, there has been a remarkable increase of the proportion of HCC among chronic liver diseases (CLD) patients from 4.0% to 7.2% over a decade. This rising proportion may be explained by the increasing risk factors such as the emergence of hepatitis C virus (HCV) over the same period of time, the contribution of hepatitis B virus (HBV) infection, improvement of the screening programs and diagnostic tools of HCC as well as the increased survival rate among patients with cirrhosis to allow time for some of them to develop HCC .
Hepatocellular carcinoma is multifactorial in etiology and complex in pathogenesis, the blend of risk factors differs in different parts of the world, and this may explain in part the diverse biologic characteristics of HCC in different populations .
Exposure to aflatoxin is an additional risk factor for the development of HCC, through damage of DNA in liver cells and mutation in p53 tumor suppressor gene . A previous study showed that aflatoxin B1 has a considerable role in the development of HCC among Egyptians .
Clinical studies have shown that AFB1 selectively targets at the third base position of codon 249 of the human p53 gene, a known mutational hotspot in human hepatocellular carcinoma (HCC) . A significant association between aflatoxin exposure and HCC has been reported in hyperendemic areas . A synergistic interaction between AFB1 exposure and viral hepatitis B (HBV) infection on HCC risk has been reported in several epidemiologic studies.
Aflatoxin exposure may be associated with advanced liver disease in chronic hepatitis C (HCV) patients. Levels of AFB1-albumin/albumin were significantly related to ultrasono-graphic hepatic parenchyma scores in anti-HCV-positive subjects .
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Hepatocellular carcinoma (HCC) | Other | Estimation of serum aflatoxin level in 40 patients with hepatocellular carcinoma (HCC) |
|
| 20 cirrhotic patients | Other | Estimation of serum aflatoxin level in 20 patients with liver cirrhosis |
|
| Control group | Other | Estimation of serum aflatoxin level in 15 individuals, as a control group in patient house whom share the same quality of life and whom were neither HCC patients nor cirrhotic patients, were invited to share in the study |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Aflatoxin | Other | Evaluation of Aflatoxin level |
|
| Measure | Description | Time Frame |
|---|---|---|
| Serum Aflatoxin Level in Liver Cancer Patients | Serum aflatoxin level in liver cancer patients in comparison to liver cirrhosis and controls. | 6 months |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Mohamed Sharaf-eldin, Prof | hepatology dept-Tanta | Principal Investigator |
| Raafat Salah, Professor | hepatology dept-Tanta | Study Director |
| hanan Soliman, Prof | hepatology dept-Tanta | Study Chair |
| Sherief abd-elsalm, lecturer | hepatology dept-Tanta | Study Chair |
| Walaa Elkhalawany, lecturer | hepatology dept-Tanta | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Tanta university - faculty of medicine | Cairo | Elgharbia | Egypt |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Hepatocellular Carcinoma (HCC) | Estimation of serum aflatoxin level in 160 patients with hepatocellular carcinoma (HCC) Aflatoxin: Evaluation of Aflatoxin level |
| FG001 | Cirrhotic Patients | Estimation of serum aflatoxin level in 80 patients with liver cirrhosis Aflatoxin: Evaluation of Aflatoxin level |
| FG002 | Control Group | Estimation of serum aflatoxin level in 60 individuals, as a control group in patient house whom share the same quality of life and whom were neither HCC patients nor cirrhotic patients, were invited to share in the study Aflatoxin: Evaluation of Aflatoxin level |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Hepatocellular Carcinoma (HCC) | Estimation of serum aflatoxin level in 160 patients with hepatocellular carcinoma (HCC) Aflatoxin: Evaluation of Aflatoxin level |
| BG001 | Cirrhotic Patients |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Age, categorical numerical |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Serum Aflatoxin Level in Liver Cancer Patients | Serum aflatoxin level in liver cancer patients in comparison to liver cirrhosis and controls. | Posted | Mean | Standard Deviation | ng\ml | 6 months |
|
2 years
0 means no side effects
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Hepatocellular Carcinoma (HCC) | Estimation of serum aflatoxin level in 160 patients with hepatocellular carcinoma (HCC) Aflatoxin: Evaluation of Aflatoxin level |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Sherief Abd-Elsalam | Tanta university | 00201095159522 | sherif_tropical@yahoo.com |
Not provided
| ID | Term |
|---|---|
| D008113 | Liver Neoplasms |
| ID | Term |
|---|---|
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D004066 | Digestive System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000348 | Aflatoxins |
| ID | Term |
|---|---|
| D001578 | Benzopyrans |
| D011714 | Pyrans |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
No Masking
Not provided
Estimation of serum aflatoxin level in 80 patients with liver cirrhosis
Aflatoxin: Evaluation of Aflatoxin level
| BG002 | Control Group | Estimation of serum aflatoxin level in 60 individuals, as a control group in patient house whom share the same quality of life and whom were neither HCC patients nor cirrhotic patients, were invited to share in the study Aflatoxin: Evaluation of Aflatoxin level |
| BG003 | Total | Total of all reporting groups |
| Count of Participants |
| Participants |
|
| Age, Continuous | Mean | Standard Deviation | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
Estimation of serum aflatoxin level in 60 individuals, as a control group in patient house whom share the same quality of life and whom were neither HCC patients nor cirrhotic patients, were invited to share in the study Aflatoxin: Evaluation of Aflatoxin level |
|
|
| 0 |
| 160 |
| 0 |
| 160 |
| EG001 | Cirrhotic Patients | Estimation of serum aflatoxin level in 80 patients with liver cirrhosis Aflatoxin: Evaluation of Aflatoxin level | 0 | 80 | 0 | 80 |
| EG002 | Control Group | Estimation of serum aflatoxin level in 60 individuals, as a control group in patient house whom share the same quality of life and whom were neither HCC patients nor cirrhotic patients, were invited to share in the study Aflatoxin: Evaluation of Aflatoxin level | 0 | 60 | 0 | 60 |
Not provided
Not provided
| D008107 |
| Liver Diseases |
| D006574 |
| Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D009183 | Mycotoxins |
| D014118 | Toxins, Biological |
| D001685 | Biological Factors |